Christina Willwerth - Net Worth and Insider Trading

Christina Willwerth Net Worth

The estimated net worth of Christina Willwerth is at least $1 Million dollars as of 2024-04-29. Christina Willwerth is the Chief Strategy Officer of Flexion Therapeutics Inc and owns about 141,241 shares of Flexion Therapeutics Inc (FLXN) stock worth over $1 Million. Details can be seen in Christina Willwerth's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Christina Willwerth has not made any transactions after 2021-07-19 and currently still holds the listed stock(s).

Transaction Summary of Christina Willwerth

To

Christina Willwerth Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Christina Willwerth owns 1 companies in total, including Flexion Therapeutics Inc (FLXN) .

Click here to see the complete history of Christina Willwerth’s form 4 insider trades.

Insider Ownership Summary of Christina Willwerth

Ticker Comapny Transaction Date Type of Owner
FLXN Flexion Therapeutics Inc 2021-07-19 Chief Strategy Officer

Christina Willwerth Latest Holdings Summary

Christina Willwerth currently owns a total of 1 stock. Christina Willwerth owns 141,241 shares of Flexion Therapeutics Inc (FLXN) as of July 19, 2021, with a value of $1 Million.

Latest Holdings of Christina Willwerth

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
FLXN Flexion Therapeutics Inc 2021-07-19 141,241 9.12 1,288,118

Holding Weightings of Christina Willwerth


Christina Willwerth Form 4 Trading Tracker

According to the SEC Form 4 filings, Christina Willwerth has made a total of 2 transactions in Flexion Therapeutics Inc (FLXN) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Flexion Therapeutics Inc is the sale of 3,945 shares on July 19, 2021, which brought Christina Willwerth around $25,445.

Insider Trading History of Christina Willwerth

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Christina Willwerth Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Christina Willwerth Ownership Network

Ownership Network List of Christina Willwerth

No Data

Ownership Network Relation of Christina Willwerth


Christina Willwerth Owned Company Details

What does Flexion Therapeutics Inc do?

Who are the key executives at Flexion Therapeutics Inc?

Christina Willwerth is the Chief Strategy Officer of Flexion Therapeutics Inc. Other key executives at Flexion Therapeutics Inc include Chief Regulatory Officer Kerry Wentworth , General Counsel Mark S. Levine , and Chief Financial Officer David Arkowitz .

Flexion Therapeutics Inc (FLXN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Flexion Therapeutics Inc (FLXN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Flexion Therapeutics Inc (FLXN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Flexion Therapeutics Inc (FLXN)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Flexion Therapeutics Inc Insider Transactions

No Available Data

Christina Willwerth Mailing Address

Above is the net worth, insider trading, and ownership report for Christina Willwerth. You might contact Christina Willwerth via mailing address: C/o Flexion Therapeutics, Inc. 10 Mall Road, Suite 301 Burlington Ma 01803.

Discussions on Christina Willwerth

No discussions yet.